Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2025
Context: The filing serves as a Regulation FD disclosure to announce the timing of a conference call regarding the two-year results of the CardiAMP-HF clinical trial.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on event disclosure rather than financial performance reporting.
Material Changes
No material financial changes or operational updates are detailed in this filing. The primary event is the scheduling clarification for the upcoming investor conference call.
Guidance, Outlook, and Management Commentary
- Event: A conference call to address the two-year CardiAMP-HF results is scheduled for March 31, 2025, at 4:30 PM EDT.
- Access: The call is available via live webcast and telephone dial-in. Registration is required for dial-in numbers, though unregistered parties may call in and request to be joined.
- Replay: Webcast and telephonic replays will be available approximately one hour after the call concludes.
- Legal Status: The information in Item 7.01 and the attached press release (Exhibit 99.1) is furnished and not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific clinical outcomes of the two-year CardiAMP-HF trial during the March 31, 2025 conference call.
- Confirm the company's cash runway and funding status, as this 8-K does not contain updated financial statements.
- Review the attached press release (Exhibit 99.1) for any additional context on the trial results not included in the 8-K summary.
- Monitor subsequent filings for any material changes to the company's financial position resulting from the trial results.